Jordan Unveils State of the Art Healthcare Technology in Hospital Trial
27th October 2009 AMMAN, Jordan, October 27 /PRNewswire/ -- The Hashemite Kingdom of Jordan, in a public demonstration today hosted
by His Majesty King Abdullah II, provided a stunning look at the new
integrated...
Shire Targets Fourth Quarter Filing of BLA for REPLAGAL(R) for Fabry Disease With U.S. FDA
21st October 2009 CAMBRIDGE, Massachusetts, October 21 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, announces plans to file a Biologics License
Application (BLA)...
Thermo Fisher Scientific's Biomarker B-R-A-H-M-S PCT (Procalcitonin) Included in S3 Guidelines
19th October 2009 HENNIGSDORF, Germany, October 19 /PRNewswire/ -- Thermo Fisher Scientific Inc., the world leader in serving
science, today announced that its biomarker, B-R-A-H-M-S PCT (procalcitonin),
has been...
Shire and Sandoz Settle all Pending Litigation Concerning ADDERALL XR(R)
13th October 2009 PHILADELPHIA, October 13 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty
biopharmaceutical company, announces that it has settled all pending
litigation with Sandoz, Inc....
The Queensland Facility for Advanced Bioinformatics Selects IPA in Multi-Year Deal for Systems Biology Effort
6th October 2009 REDWOOD CITY, California, October 6 /PRNewswire/ -- Ingenuity Systems, the leading provider of information solutions for life
science researchers, and Millennium Science, Ingenuity Systems'...
Onglyza(R) (saxagliptin) Receives Marketing Authorisation in Europe for the Treatment of Type 2 Diabetes
5th October 2009 PARIS and LONDON, October 5 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN)
(LSE: AZN) announced today that the European Commission has granted...
Sanofi Aventis : Multaq(R) (dronedarone) Recommended for Approval in the European Union
25th September 2009 PARIS, September 25 /PRNewswire/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today
that the Committee for Medicinal Products for Human Use (CHMP) of the
European Medicines Agency (EMEA)...
Afinitor(R) (everolimus) Now Licensed in UK for Advanced Kidney Cancer Patients After Failure of First Line Vascular Targeted Therapy (1,2)
24th September 2009 FRIMLEY, England, September 24 /PRNewswire/ -- Afinitor(R) (everolimus) has recently been licensed for the treatment of
advanced kidney cancer after failure of treatments which prevent the growth...
Novasep Gains SafeBridge(R) "Potent Compound Safety Certification" for its Le Mans Facility
17th September 2009 POMPEY, France, September 17 /PRNewswire/ -- Novasep is pleased to announce that its site in Le Mans -
France, specialized in the development and manufacturing of Highly Potent
Active Pharmaceutical...
Pieris AG Enters into Anticalin Collaboration With Allergan, Inc.
15th September 2009 FREISING-WEIHENSTEPHAN, Germany, September 15 /PRNewswire/ -- Pieris AG today announced that they have entered into a collaboration
agreement with Allergan, Inc. (NYSE: AGN) that combines Pieris'...
Forest Laboratories UK Ltd Submits Marketing Authorisation Application for the First Dry Powder Inhalation Antibiotic for Cystic Fibrosis Patients
15th September 2009 LONDON, September 15 /PRNewswire/ -- Forest Laboratories UK Ltd, (a wholly owned subsidiary of Forest
Laboratories Inc) announced that following the successful completion of its
pan-European...
Accumetrics, Inc. Forms Partnership With Grifols as Its Distributor in Spain, Portugal and Chile
2nd September 2009 SAN DIEGO, September 2 /PRNewswire/ -- Accumetrics, Inc. has announced the signing of a new exclusive
distribution agreement for its VerifyNow(R) System in Spain, Portugal and
Chile with Grifols...
Wyeth's Torisel Approved by European Commission for the Treatment of Relapsed and/or Refractory Mantle Cell Lymphoma
27th August 2009 MAIDENHEAD, England, August 27 /PRNewswire/ -- Wyeth Europa Ltd., a division of Wyeth (NYSE: WYE), announced today that
the European Commission has approved the mTOR (mammalian target of...
Ingenuity's Technology Powers BD Cell Pathways Tool on New BD Biosciences Website
11th August 2009 REDWOOD CITY, California, August 11 /PRNewswire/ -- Ingenuity Systems today announced that BD Biosciences, a segment of BD
(Becton, Dickinson and Company), is integrating Ingenuity's Knowledge...
Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
4th August 2009 PALO ALTO, California, August 4 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc., a biotechnology company developing
antiviral therapies, announced today that it has licensed the exclusive
worldwide...
Nuevolution Announces Worldwide Technology Cross-Licensing Agreement With GSK
28th July 2009 COPENHAGEN, Denmark, July 28 /PRNewswire/ -- Nuevolution today announced the execution of a worldwide
technology cross-licensing agreement with GlaxoSmithKline.
The agreement relates to a number...
Cellestis Appoints BioChemMack as New Commercial Partner in Russia
23rd July 2009 MOSCOW, July 23 /PRNewswire/ -- Cellestis is pleased to introduce BioChemMack (Moscow, Russia) as its
newly appointed commercial partner for distribution of the tuberculosis blood
test,...
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
